AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership
Galderma will present eight posters spanning its full Injectable Aesthetics portfolio at AMWC Dubai 2026, highlighting the complementary benefits of Sculptra® and Restylane®, and pooled phase III study data for Relfydess® (relabotulinumtoxinA)1-8 With 30 years of innovation, Restylane continues to evolve through the development of new technologies and expanded clinical indications, with data to…
Galderma, a company headquartered in Zug, Switzerland, is set to showcase its leading Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, United Arab Emirates, from October 21-23, 2026. The company will present eight scientific abstracts, alongside a symposium and six Meet-the-Expert sessions, all highlighting the expanding benefits of Relfydess, Sculptra, and the Restylane range.
These data demonstrate Galderma's commitment to meeting the evolving needs of patients and healthcare professionals through innovation that addresses growing needs, from menopause-related skin changes and regenerative aesthetic solutions, to body indications.
Brief written by urgent.news from Financial Post's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
